Seasoned investors tend to closely follow the ups and downs of the market.

The Investment Committee give you their top stocks to watch for the second half.

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Partners with Massachusetts General Hosp. for Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate.

The S&P 500 index came close to correction territory on Aug. 2, after falling about 5.7% from a peak it reached in mid-July. With drugs that some of us can't live without, Bristol Myers Squibb hasn't lowered its dividend payment in 25 years.

The tech rally is losing steam as economic indicators, including rising unemployment and weak manufacturing data, suggest increasing recession risks. Investors are shifting focus from high-growth tech to value stocks, driven by concerns over valuation and a slowing economic outlook. In this uncertain environment, finding quality investments with solid balance sheets and growth potential is key to navigating potential market turbulence.

The Investment Committee give you their top stocks to watch for the second half.

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 NORTH CHICAGO, Ill. , Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE).

Long-term outlook is crucial in investing, short-term gains may be attractive but can turn out to be bad if continued. AbbVie is a successful example of a newly-listed company that has turned out to be a great long-term investment. Kenvue and Sila Realty Trust are two newly-listed companies that could potentially reward investors similarly to AbbVie.

Understanding companies' fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages.

Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate.